Sunshine Biopharma (SBFM)
NASDAQ:SBFM
Want to see SBFM full AI Analyst Report?
Total Valuation
Sunshine Biopharma has a market cap or net worth of $4.82M. The enterprise value is -$3.57M.
Market Cap$4.82M
Enterprise Value-$3.57M
Share Statistics
Sunshine Biopharma has 4,905,945 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding4,905,945
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Sunshine Biopharma’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -18.78%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-18.78%
Return on Capital Employed (ROCE)-0.19
Revenue Per Employee698.19K
Profits Per Employee-114.91K
Employee Count52
Asset Turnover1.21
Inventory Turnover1.81
Valuation Ratios
The current PE Ratio of Sunshine Biopharma is ―. Sunshine Biopharma’s PEG ratio is 0.01.
PE Ratio―
PS Ratio0.14
PB Ratio0.22
Price to Fair Value0.22
Price to FCF-0.93
Price to Operating Cash Flow-0.75
PEG Ratio0.01
Income Statement
In the last 12 months, Sunshine Biopharma had revenue of 36.31M and earned -5.98M in profits. Earnings per share was -1.44.
Revenue36.31M
Gross Profit11.92M
Operating Income-4.48M
Pretax Income-5.95M
Net Income-5.98M
EBITDA-4.15M
Earnings Per Share (EPS)-1.44
Cash Flow
In the last 12 months, operating cash flow was -5.33M and capital expenditures -26.10K, giving a free cash flow of -5.36M billion.
Operating Cash Flow-5.33M
Free Cash Flow-5.36M
Free Cash Flow per Share-1.09
Dividends & Yields
Sunshine Biopharma pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.35
52-Week Price Change-27.48%
50-Day Moving Average1.11
200-Day Moving Average1.39
Relative Strength Index (RSI)46.84
Average Volume (3m)1.09M
Important Dates
Sunshine Biopharma upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateNov 11, 2025
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Sunshine Biopharma as a current ratio of 4.17, with Debt / Equity ratio of 3.53%
Current Ratio4.17
Quick Ratio2.08
Debt to Market Cap0.04
Net Debt to EBITDA2.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Sunshine Biopharma has paid 21.61K in taxes.
Income Tax21.61K
Effective Tax Rate>-0.01
Enterprise Valuation
Sunshine Biopharma EV to EBITDA ratio is 0.77, with an EV/FCF ratio of 0.58.
EV to Sales-0.09
EV to EBITDA0.77
EV to Free Cash Flow0.58
EV to Operating Cash Flow0.60
Balance Sheet
Sunshine Biopharma has $9.12M in cash and marketable securities with $812.42K in debt, giving a net cash position of $8.31M billion.
Cash & Marketable Securities$9.12M
Total Debt$812.42K
Net Cash$8.31M
Net Cash Per Share$1.69
Tangible Book Value Per Share$5.09
Margins
Gross margin is 33.48%, with operating margin of -12.34%, and net profit margin of -16.46%.
Gross Margin33.48%
Operating Margin-12.34%
Pretax Margin-16.40%
Net Profit Margin-16.46%
EBITDA Margin-11.42%
EBIT Margin-12.34%
Analyst Forecast
The average price target for Sunshine Biopharma is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast4.11%
EPS Growth Forecast97.13%